WilmerHale Represents Karyopharm Therapeutics in Pricing of $150M of Convertible Senior Notes

• 10.19.2018

On Thursday, October 11, 2018, Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due in 2025. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933. Karyopharm also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes.

The WilmerHale team representing Karyopharm in the sale consisted of Jason Kropp, Erika Robinson, John Sigel, Craig Hilts, Tim Kulis and Meghan Walsh. 

Read Karyopharm’s press release regarding the sale.